Liquidia Corporation (LQDA) - News Archive

Liquidia Corporation has recently announced a significant milestone in its journey to bring YUTREPIA (treprostinil) inhalation powder to market. The U.S. Food and Drug Administration (FDA) has officially accepted the co...

Advancements in Inhaled Therapies: Liquidia and Pharmosa Biopharm Strengthen Collaboration on Sustained Release Treprostinil Innovative pharmaceutical solutions continue to evolve as global health challenges demand more...

In a recent breakthrough for Liquidia Corporation, the U.S. District Court for the District of Delaware has set aside an injunction that had previously prevented the U.S. Food and Drug Administration (FDA) from issuing...

In a recent development in the pharmaceutical industry, Liquidia Corporation (NASDAQ: LQDA) has filed its response and counterclaims against United Therapeutics Corporation (UTHR). This legal battle revolves around alle...

Liquidia Corporation, a leading pharmaceutical company, recently shared an update on the development of its extensive clinical pipeline programs aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hype...

Liquidia Corporation Secures $100 Million in New Capital, Enhancing Financial PositionMORRISVILLE, N.C., Jan. 04, 2024 - Liquidia Corporation (NASDAQ: LQDA), a cutting-edge biopharmaceutical company specializing in the...